GlassScriptPhysician profile
Laurie Douglas
NPI 1013173590
$3,834.27
in general payments reported to CMS, 2019-2025
40 companies · $661 in 2025
The $661 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $257 · 2021: $229 · 2022: $631 · 2023: $706 · 2024: $853 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.43 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $491.66 | 2019-2025 | Rybrevant, Carvykti, Tecvayli |
| Astellas Pharma US INC | $405.28 | 2019-2025 | Xtandi, Vyloy, Xospata |
| E.R. Squibb & Sons, L.L.C. | $276.16 | 2020-2024 | Reblozyl, Opdivo |
| Celgene Corporation | $265.76 | 2022-2024 | Reblozyl, Opdualag, Pomalyst |
| Pfizer INC. | $259.37 | 2019-2025 | |
| Abbvie INC. | $245.90 | 2023-2025 | Venclexta |
| Octapharma USA, INC. | $213.05 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Kite Pharma, INC. | $143.27 | 2019-2025 | Yescarta |
| Glaxosmithkline, LLC. | $142.13 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $141.55 | 2021-2025 | Trodelvy |
| Incyte Corporation | $124.27 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $100.98 | 2021-2025 | Enhertu |
| Genzyme Corporation | $89.29 | 2019-2024 | |
| Deciphera Pharmaceuticals INC. | $88.74 | 2023-2025 | Qinlock, Tgct |
| Myriad Genetic Laboratories, INC. | $86.63 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Douglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.